Who We Are
Next-Generation Solutions in Cancer Therapeutics
Who We Are
Who We Are
At 7 Primus Biosciences, we transform early-stage scientific discoveries into groundbreaking cancer therapeutics that improve patient outcomes. By leveraging our extensive expertise in oncology and drug development, we utilize proprietary platforms to precisely target tumor- associated antigens. Our mission is to pioneer potent and effective treatments that address critical unmet needs in cancer care, bringing hope and making a meaningful impact on patients worldwide.
At 7 Primus Biosciences, we transform early-stage scientific discoveries into groundbreaking cancer therapeutics that improve patient outcomes. By leveraging our extensive expertise in oncology and drug development, we utilize proprietary platforms to precisely target tumor- associated antigens. Our mission is to pioneer potent and effective treatments that address critical unmet needs in cancer care, bringing hope and making a meaningful impact on patients worldwide.
Meet our team
We are established biotech innovators, driving groundbreaking science from concept to industry leadership. Our leadership team excels at building and scaling startups, advancing them to industry recognition, strategic partnerships, and successful exits. With extensive expertise and a clear vision, we deliver competitive therapeutics and elevate 7 Primus Biosciences to an exceptional leader in the industry.
Meet our team
We are established biotech innovators, driving groundbreaking science from concept to industry leadership. Our leadership team excels at building and scaling startups, advancing them to industry recognition, strategic partnerships, and successful exits. With extensive expertise and a clear vision, we deliver competitive therapeutics and elevate 7 Primus Biosciences to an exceptional leader in the industry.
Meet our team
We are established biotech innovators, driving groundbreaking science from concept to industry leadership. Our leadership team excels at building and scaling startups, advancing them to industry recognition, strategic partnerships, and successful exits. With extensive expertise and a clear vision, we deliver competitive therapeutics and elevate 7 Primus Biosciences to an exceptional leader in the industry.
MANAGEMENT TEAM
BOARD OF DIRECTORS
Hahn-Jun Lee, M.Sc., Ph.D.
Founder/President & CEO
Dr. Lee is a visionary serial biotech entrepreneur and industry leader known for building and scaling innovative startup biotech companies that advance transformative therapies. He founded and led Epygenix Therapeutics, which Harmony Biosciences (NASDAQ: HRMY) acquired, and Polaryx Therapeutics, a pioneer in patient-centric solutions for Batten disease. Dr. Lee has a distinguished record of translating early-stage discoveries into clinical-stage assets, securing pivotal approvals from global regulatory agencies including the US FDA, Health Canada, and MHRA for IND, ODD, and RPDD designations.
In addition to that, Dr. Lee is recognized for his business acumen and strategic leadership in the biotech sector. He has forged impactful partnerships with global investors, top-tier pharmaceutical firms, and industry pioneers, consistently driving enterprise growth, accelerating innovation, and achieving successful exits.
Dr. Lee’s background includes academic appointments at prestigious institutions, where he served as Assistant Professor of Biotechnology at Columbia University’s College of Physicians and Surgeons and as Staff Scientist at the RIKEN Brain Science Institute in Japan. He earned his M.S. and Ph.D. in Applied Biotechnology from the University of Tokyo, Japan and a B.S. in Life Science from Sogang University in S. Korea.
MANAGEMENT TEAM
BOARD OF DIRECTORS
Hahn-Jun Lee, M.Sc., Ph.D.
Founder/President & CEO
Dr. Lee is a visionary serial biotech entrepreneur and industry leader known for building and scaling innovative startup biotech companies that advance transformative therapies. He founded and led Epygenix Therapeutics, which Harmony Biosciences (NASDAQ: HRMY) acquired, and Polaryx Therapeutics, a pioneer in patient-centric solutions for Batten disease. Dr. Lee has a distinguished record of translating early-stage discoveries into clinical-stage assets, securing pivotal approvals from global regulatory agencies including the US FDA, Health Canada, and MHRA for IND, ODD, and RPDD designations.
In addition to that, Dr. Lee is recognized for his business acumen and strategic leadership in the biotech sector. He has forged impactful partnerships with global investors, top-tier pharmaceutical firms, and industry pioneers, consistently driving enterprise growth, accelerating innovation, and achieving successful exits.
Dr. Lee’s background includes academic appointments at prestigious institutions, where he served as Assistant Professor of Biotechnology at Columbia University’s College of Physicians and Surgeons and as Staff Scientist at the RIKEN Brain Science Institute in Japan. He earned his M.S. and Ph.D. in Applied Biotechnology from the University of Tokyo, Japan and a B.S. in Life Science from Sogang University in S. Korea.
MANAGEMENT TEAM
BOARD OF DIRECTORS